Mint Explainer | Why India plans to end ‘double testing’ for plasma-derived medicines
Draft amendments to the Drugs Rules would remove duplicate viral tests on finished plasma-derived medicines once source plasma is verified as safe, aimed at accelerating production of critical therapies and aligning India’s standards with global pharmacopoeias.
Draft amendments to the Drugs Rules would remove duplicate viral tests on finished plasma-derived medicines once source plasma is verified as safe, aimed at accelerating production of critical therapies and aligning India’s standards with global pharmacopoeias.
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
